In its third quarter financial report, Pacira noted a 23 percent increase in Exparel net product sales, which hit $82.2 million for the quarter,. Due to recent positive coverage announcements from CMS ...

According to the American College of Surgeons, 15 million Americans undergo surgery each year. Despite this high frequency and the significant impact these procedures can have on patients, no ...

Please provide your email address to receive an email when new articles are posted on . Published results showed Exparel may be safe in patients aged 6 to younger than 17 years undergoing spine or ...

Research published in the Journal of Medical Economics examined the role Exparel plays in reducing opioid consumption and hospital costs following total knee arthroplasty surgery. Researchers ...

MIAMI (KFSN) -- Being told your child needs open heart surgery is frightening enough. A major concern is the pain after the procedure. Now a new type of anesthesia is proving to be a real game-changer ...

We issued an updated research report on Pacira Pharmaceuticals, Inc. PCRX on July 13. Pacira's top line mainly comprises contribution from its marketed product, -Exparel. Exparel is a liposome ...

An injectable anesthetic may be able to dull pain after major implant surgery. A recent study found that the bupivacaine liposome injectable suspension Exparel significantly reduced pain for patients ...

Pacira BioSciences, Inc. features 78% margins and NOPAIN Act tailwinds; its 5.5x EV/EBITDA multiple reflects patent fears.

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...

Pacira’s EXPAREL sales at $44.9M for Q2 Pacira Pharmaceuticals headquartered in Parsippany, N.J., reported the success of its EXPAREL, in the United States with net product sales totaling at $44.9 ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® ...